To learn more about advanced genomic and genetic testing for patients at Duke Medicine and partner sites around the country, visit www.genomestohealth.org

Keyserling Cancer Center

Clinical Trials

The Keyserling Cancer Center received approval from the Cancer and Leukemia Group B (CALGB) to begin a clinical trials program in 2007.

A local clinical trials program allows eligible area cancer patients the opportunity to receive cutting-edge cancer therapies that otherwise might not be available to them, while helping researchers learn more about the effectiveness of new treatments.

“Clinical trials are critical to the development of new cancer treatments, and can be life saving, or life-prolonging, to those patients who have exhausted their cancer treatment options,” says BMH Oncology Services Medical Director Majd Chahin, MD, a medical oncologist whose practice is located at the Keyserling Cancer Center. Dr. Chahin has been named principal investigator for the program.

According to Duke Oncology Network Medical Director Dr. Linda Sutton, “designation as a Duke Affiliate Member of the CALGB reflects the commitment of BMH to excellence in patient care. We have worked closely with Dr. Chahin and the staff of the Keyserling Cancer Center to develop this opportunity for their patients.”

Beaufort Memorial Keyserling Cancer Center Director Connie Duke, RN, works closely with Dr. Chahin and the Duke Oncology Network to identify trials that are appropriate for the area’s patient population. To date, many of the trials have been focused on the most common forms of cancer found in the area: lung, breast, colon and prostate.

Duke physician Neal E. Ready, MD, a medical oncologist who is active in clinical trials development, visited with physicians at Beaufort Memorial Hospital and the Beaufort Memorial Keyserling Cancer Center to formally launch the first series of trials.

“This is another example of the tremendous benefit our affiliation with Duke University Health System brings to the community,” Connie Duke says. “Without this relationship – and certainly without Duke’s guidance throughout the development of our cancer center and programs, it would have been difficult to offer local patients the opportunity to participate in clinical trials in their own community.”

To view a complete list of clinical trials currently being offered locally click here.
To learn more about clinical trials visit the National Cancer Institute website at www.cancer.gov and click on “Clinical Trials.”

About the CALGB

The Cancer and Leukemia Group B (CALGB) is a national clinical research group sponsored by the National Cancer Institute, with its Central Office headquartered at the University of Chicago and its Statistical Center located at Duke University. The CALGB was founded in 1956 with a goal of bringing together clinical oncologists and laboratory investigators to develop better treatments for cancer. Since 1956, CALGB has grown into a national network of 29 university medical centers, over 225 community hospitals and more than 3,000 oncology specialists who collaborate in clinical research studies aimed at reducing the morbidity and mortality from cancer, relating the biological characteristics of cancer to clinical outcomes and developing new strategies for the early detection and prevention of cancer.

Keyserling Cancer Center

1680 Ribaut Road
Port Royal, SC 29935